Boston Trust Walden Corp Has $70.43 Million Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Boston Trust Walden Corp lessened its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 1.5% in the first quarter, HoldingsChannel.com reports. The firm owned 819,282 shares of the company’s stock after selling 12,345 shares during the quarter. Boston Trust Walden Corp’s holdings in Prestige Consumer Healthcare were worth $70,434,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in PBH. Kestra Investment Management LLC acquired a new stake in Prestige Consumer Healthcare during the 4th quarter valued at approximately $27,000. CIBC Private Wealth Group LLC increased its position in Prestige Consumer Healthcare by 48.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock valued at $34,000 after purchasing an additional 152 shares during the period. Opal Wealth Advisors LLC acquired a new stake in Prestige Consumer Healthcare during the 1st quarter valued at approximately $38,000. Headlands Technologies LLC acquired a new stake in Prestige Consumer Healthcare during the 4th quarter valued at approximately $40,000. Finally, McIlrath & Eck LLC increased its position in Prestige Consumer Healthcare by 19.1% during the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock valued at $75,000 after purchasing an additional 154 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Price Performance

Prestige Consumer Healthcare stock opened at $83.51 on Thursday. The stock has a market capitalization of $4.13 billion, a price-to-earnings ratio of 19.47, a PEG ratio of 2.51 and a beta of 0.45. Prestige Consumer Healthcare Inc. has a 52-week low of $64.63 and a 52-week high of $90.04. The stock’s 50 day moving average price is $83.85 and its two-hundred day moving average price is $82.55. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.82 and a current ratio of 4.20.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.02. The firm had revenue of $296.52 million for the quarter, compared to analysts’ expectations of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.02 EPS. On average, equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Royal Bank Of Canada raised shares of Prestige Consumer Healthcare to a “hold” rating in a research report on Thursday, May 8th. Wall Street Zen upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Saturday, May 17th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $93.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.